Spots Global Cancer Trial Database for gene therapy
Every month we try and update this database with for gene therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma | NCT02062359 | Metastatic Canc... Metastatic Mela... | Anti-NY ESO-1 T... Aldesleukin Cyclophosphamid... Fludarabine | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer | NCT01058785 | Lung Neoplasm Carcinoma, Bron... | Lucanix | 18 Years - | NovaRx Corporation | |
| An Exploratory Trial to Evaluate Efficacy and Safety for Combination Treatment of Adenovirus Double Suicide Gene Therapy | NCT04739046 | Pancreas Cancer | Theragene arm | 19 Years - 75 Years | Seoul National University Bundang Hospital | |
| An Exploratory Trial to Evaluate Efficacy and Safety for Combination Treatment of Adenovirus Double Suicide Gene Therapy | NCT04739046 | Pancreas Cancer | Theragene arm | 19 Years - 75 Years | Seoul National University Bundang Hospital | |
| Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers | NCT03680560 | Solid Tumor HER-2 Protein O... | ACTR T Cell Pro... Trastuzumab | 18 Years - 75 Years | Cogent Biosciences, Inc. | |
| A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | NCT03970382 | Solid Tumor | NeoTCR-P1 adopt... nivolumab IL-2 | 18 Years - | PACT Pharma, Inc. | |
| Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies | NCT00451022 | Prostate Cancer Liver Cancer Breast Cancer Colon Cancer Lung Cancer | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC) | NCT05003895 | Hepatocellular ... Hepatocellular ... Metastatic Hepa... | Cyclophosphamid... CAR-T cell Fludarabine | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas | NCT00031083 | Glioblastoma Mu... Anaplastic Astr... Oligoastrocytom... Gliosarcoma | Interferon-beta | 18 Years - | Biogen | |
| Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer | NCT00005785 | Hematologic Neo... HIV Infection | GCSF Mobilized ... | - | National Institutes of Health Clinical Center (CC) | |
| Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma | NCT02062827 | Recurrent Gliob... Progressive Gli... Anaplastic Astr... | M032 (NSC 73397... | 18 Years - | University of Alabama at Birmingham | |
| Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma | NCT02215967 | Myeloma, Plasma... Myeloma-Multipl... | Cyclophosphamid... Fludarabine Anti-B-cell mat... | 18 Years - 73 Years | National Institutes of Health Clinical Center (CC) | |
| Safety and Efficacy Study Using Rexin-G for Sarcoma | NCT00505713 | Sarcoma | Rexin-G Rexin-G Rexin-G Rexin-G Rexin-G | 10 Years - | Epeius Biotechnologies | |
| rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors | NCT00902122 | Advanced Malign... | rAd-p53 gene surgery p53 gene therap... p53 gene therap... | 18 Years - 85 Years | Shenzhen SiBiono GeneTech Co.,Ltd | |
| Liver Transplantation With ADV-TK Gene Therapy Improves Survival in Patients With Advanced Hepatocellular Carcinoma | NCT00300521 | Hepatocellular ... Liver Transplan... | ADV-TK (adenovi... | 0 Years - | Beijing Chao Yang Hospital | |
| E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | NCT05686226 | Cervical Cancer Throat Cancer Oropharynx Canc... Anal Cancer Vulva Cancer Vaginal Cancer Penile Cancer Metastatic Canc... HPV-Related Mal... HPV-Related Car... HPV-Related Cer... HPV-Related Squ... HPV-Related Ade... HPV Positive Or... HPV-Associated ... HPV-Related Ade... HPV-Related End... HPV-Related Ana... HPV-Related Pen... HPV-Related Vul... HPV Positive Re... | E7 TCR-T cells | 18 Years - | Rutgers, The State University of New Jersey | |
| Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma | NCT02202564 | Liver Cancer Hepatocellular ... | LT ADV-TK ganciclovir | 18 Years - 70 Years | Huazhong University of Science and Technology | |
| Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma | NCT00902044 | Sarcoma | Autologous HER2... Fludarabine Cyclophosphamid... Autologous CAR ... | - | Baylor College of Medicine | |
| CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL) | NCT01195480 | Acute Lymphobla... | donor-derived E... Irradiated dono... | - 18 Years | University College, London | |
| Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes | NCT02870244 | Melanoma | Escalating Dose... | 18 Years - 89 Years | Loyola University | |
| CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) | NCT03774654 | Refractory B-Ce... Refractory B-Ce... Relapsed Adult ... Relapsed CLL Relapsed Non Ho... | CD19.CAR-aNKT c... | 3 Years - 75 Years | Baylor College of Medicine | |
| Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells | NCT03535246 | Cancer | Engineered Immu... | 1 Year - 80 Years | Shenzhen Geno-Immune Medical Institute | |
| Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer | NCT01457131 | Metastatic Canc... Metastatic Mela... Metastatic Rena... | Fludarabine Cyclophosphamid... IL-12 & Ant... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Gene-activated Bone Substitute for Maxillofacial Bone Regeneration | NCT03076138 | Bone Cysts Bone Atrophy Bone Deformity Bone Fracture Bone Loss Tooth Loss | Gene-activated ... | 18 Years - 60 Years | Histograft Co., Ltd. | |
| Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas | NCT00751270 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... | AdV-tk Valacyclovir | 18 Years - | Candel Therapeutics, Inc. | |
| Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients | NCT00706992 | Melanoma | ALVAC-MART-1 va... MART-1:26-35(27... Aldesleukin autologous anti... incomplete Freu... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM) | NCT03875495 | Multiple Myelom... | Temferon | 18 Years - 70 Years | Genenta Science | |
| Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer | NCT00670748 | Metastatic Mela... Metastatic Rena... Metastatic Canc... | Anti-NY ESO-1 T... aldesleukin Cyclophosphamid... fludarabine pho... ALVAC NY ESO-1 ... | 18 Years - 66 Years | National Institutes of Health Clinical Center (CC) | |
| A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT | NCT03866109 | Glioblastoma Mu... | Temferon | 18 Years - 70 Years | Genenta Science | |
| p53 Gene Therapy for Head and Neck Malignant Tumors in Advanced Stage | NCT00894153 | Neoplasms | chemotherapy pl... chemotherapy radiotherapy | 18 Years - 65 Years | Shenzhen SiBiono GeneTech Co.,Ltd | |
| Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer | NCT02390739 | Metastatic Thyr... | Aldesleukin Fludarabine Cyclophosphamid... Anti-Thyroglobu... | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer | NCT00006033 | Head and Neck C... | gene therapy interleukin-2 g... methotrexate | 18 Years - | National Cancer Institute (NCI) | |
| T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer | NCT01967823 | Melanoma Meningioma Breast Cancer Non-Small Cell ... Hepatocellular ... | Anti-NY ESO-1 m... Cyclophosphamid... Fludarabine Aldesleukin | 15 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Vector Delivery of the IL-12 Gene in Men With Prostate Cancer | NCT00406939 | Prostatic Neopl... Prostate Cancer | IL-12 gene | 18 Years - | Baylor College of Medicine | |
| Study of the P16 Gene as a Predictor of Myelosuppression in Breast Cancer Patients | NCT01305954 | Breast Cancer | 18 Years - | UNC Lineberger Comprehensive Cancer Center | ||
| Study of a DNA Immunotherapy to Treat Melanoma | NCT01138410 | Malignant Melan... | SCIB1 | 18 Years - | Scancell Ltd | |
| HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA | NCT02379520 | Human Papilloma... Human Papilloma... Human Papilloma... Human Papilloma... Human Papilloma... Human Papilloma... | HPV Specific T ... Cytoxan Fludarabine Nivolumab | 18 Years - | Baylor College of Medicine | |
| Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies | NCT05797233 | Chronic Lymphoc... B-Cell Chronic ... Lymphoma, B-Cel... | Anti-CD19 and a... Cyclophosphamid... Fludarabine | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| NP2 Enkephalin For Treatment of Intractable Cancer Pain | NCT01291901 | Intractable Pai... Neoplasms | NP2 Placebo | 18 Years - | Diamyd Inc | |
| Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas | NCT00751270 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... | AdV-tk Valacyclovir | 18 Years - | Candel Therapeutics, Inc. | |
| Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes | NCT00509288 | Melanoma Skin Cancer | autologous anti... Cyclophosphamid... Fludarabine Aldesleukin autologous anti... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas | NCT00751270 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... | AdV-tk Valacyclovir | 18 Years - | Candel Therapeutics, Inc. | |
| Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed/Refractory Neuroblastoma | NCT00186862 | Neuroblastoma | Interleukin-2 | - 21 Years | St. Jude Children's Research Hospital | |
| rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant Tumors | NCT00902083 | Advanced Oral a... | p53 gene with s... surgery p53 with chemot... p53 gene therap... | 18 Years - 85 Years | Shenzhen SiBiono GeneTech Co.,Ltd | |
| LTFU for All Cell and Gene Therapy Studies | NCT06194461 | Hepatocellular ... Prostate Cancer | AZD5851 AZD0754 | 18 Years - 130 Years | AstraZeneca | |
| Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib | NCT04486833 | Carcinoma, Non-... | quaratusugene o... osimertinib Platinum-Based ... | 18 Years - | Genprex, Inc. | |
| Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy | NCT04911166 | Non-small Cell ... | Atezolizumab an... | 18 Years - | The Methodist Hospital Research Institute | |
| GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC) | NCT05003895 | Hepatocellular ... Hepatocellular ... Metastatic Hepa... | Cyclophosphamid... CAR-T cell Fludarabine | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies | NCT00451022 | Prostate Cancer Liver Cancer Breast Cancer Colon Cancer Lung Cancer | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients | NCT00706992 | Melanoma | ALVAC-MART-1 va... MART-1:26-35(27... Aldesleukin autologous anti... incomplete Freu... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Gene Therapy for Pleural Malignancies | NCT00299962 | Pleural Mesothe... Metastatic Pleu... | Adenoviral-medi... SCH 721015 | 18 Years - | University of Pennsylvania | |
| Safety and Efficacy Study Using Rexin-G for Sarcoma | NCT00505713 | Sarcoma | Rexin-G Rexin-G Rexin-G Rexin-G Rexin-G | 10 Years - | Epeius Biotechnologies | |
| Gene Therapy for the Treatment of Brain Tumors | NCT00001328 | Brain Neoplasm Neoplasm Metast... | Cytovene (Ganci... G1TKSVNa.53 Pro... | 19 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing | NCT00381173 | Breast Cancer Ovarian Cancer Prostate Cancer Colon Cancer Renal Cancer | Cyclophosphamid... | 18 Years - | Eisai Inc. | |
| Gene Transfer for Cancer Pain | NCT00804076 | Cancer Pain | NP2 | 18 Years - | Diamyd Inc | |
| Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products | NCT00695279 | Severe Combined... Malignancy, Hem... Neuroblastoma Neoplasm Mucopolysacchar... | Venipuncture | - | St. Jude Children's Research Hospital | |
| T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma | NCT02062359 | Metastatic Canc... Metastatic Mela... | Anti-NY ESO-1 T... Aldesleukin Cyclophosphamid... Fludarabine | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas | NCT01172964 | Adult Anaplasti... Recurrent Grade... Recurrent Grade... Adult Anaplasti... Adult Brain Tum... Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Adult Mixed Gli... Recurrent Adult... Adult Anaplasti... Recurrent High ... | flucytosine polymerase chai... immunohistochem... gene therapy pharmacological... 3-Tesla magneti... laboratory biom... therapeutic con... E. coli CD-expr... | 13 Years - | City of Hope Medical Center | |
| Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies | NCT05797233 | Chronic Lymphoc... B-Cell Chronic ... Lymphoma, B-Cel... | Anti-CD19 and a... Cyclophosphamid... Fludarabine | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma | NCT03284268 | Retinoblastoma,... | VCN-01 | 1 Year - 12 Years | Fundació Sant Joan de Déu | |
| Phase II Trial of Allovectin-7® for Metastatic Melanoma | NCT00044356 | Melanoma Metastatic Mela... Malignant Melan... Skin Cancer | Allovectin-7® | 18 Years - | Vical | |
| Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies | NCT00451022 | Prostate Cancer Liver Cancer Breast Cancer Colon Cancer Lung Cancer | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies | NCT02659943 | Lymphoma, B-Cel... Lymphoma, Non-h... | Anti-cluster of... Cyclophosphamid... Fludarabine | 18 Years - 73 Years | National Institutes of Health Clinical Center (CC) | |
| Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer | NCT05062980 | Non Small Cell ... | quaratusugene o... pembrolizumab docetaxel ramucirumab Investigator's ... | 18 Years - | Genprex, Inc. | |
| Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme | NCT03170141 | Glioblastoma Mu... Glioblastoma Mu... | Antigen-specifi... | 1 Year - 80 Years | Shenzhen Geno-Immune Medical Institute | |
| Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies | NCT00923026 | Melanoma Adenocarcinoma Carcinoma NOS Neuroendocrine ... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors | NCT02283489 | Head and Neck N... | recombinant hum... Cisplatin injec... Paclitaxel inje... | 18 Years - 70 Years | Chengdu Shi Endor Biological Engineering Technology Co., Ltd | |
| Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes | NCT02870244 | Melanoma | Escalating Dose... | 18 Years - 89 Years | Loyola University | |
| Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation | NCT01087294 | Leukemia, B-cel... Lymphoma, Hodgk... Lymphoma, Non-h... Lymphoma, B-Cel... | Allogeneic stem... Anti-CD19-chime... Leukapheresis | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cancer | NCT00001493 | Breast Neoplasm... Neoplasm Metast... | peripheral bloo... | - | National Institutes of Health Clinical Center (CC) | |
| Phase II Trial of Allovectin-7® for Head and Neck Cancer | NCT00050388 | Head and Neck C... Squamous Cell C... Head and Neck N... Carcinoma of th... | Allovectin-7® | 18 Years - | Vical | |
| Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab | NCT04536922 | Metastatic HPV-... | Cyclophosphamid... Fludarabine Aldesleukin Pembrolizumab (... Individual Pati... | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| MVX-ONCO-1 in Patients With Solid Tumor | NCT02193503 | Solid Tumor Cancer | Treatment | 18 Years - | Maxivax SA | |
| Phase I - Pre-Radical Prostatectomy RTVP-1 Gene Therapy for Prostate Cancer | NCT00403221 | Prostatic Neopl... | RTVP-1 Gene | 18 Years - | Baylor College of Medicine | |
| Safety and Efficacy of Targeted Gene Transfer in Colorectal Cancer Metastatic to Liver | NCT00035919 | Colorectal Neop... | Mx-dnG1 Retrovi... | 18 Years - | University of Southern California | |
| NP2 Enkephalin For Treatment of Intractable Cancer Pain | NCT01291901 | Intractable Pai... Neoplasms | NP2 Placebo | 18 Years - | Diamyd Inc | |
| CIBMTR Research Database | NCT01166009 | Autologous Stem... Allogeneic Stem... Solid Tumors Blood Cancers CAR-T Gene Therapy Non-malignant D... | - | Center for International Blood and Marrow Transplant Research | ||
| 3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA | NCT02439788 | Neuroblastoma | cyclophosphamid... Fludarabine GINAKIT Cells | 1 Year - 18 Years | Baylor College of Medicine | |
| Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma | NCT03266692 | Multiple Myelom... Multiple Myelom... Refractory Mult... | ACTR087 SEA-BCMA | 18 Years - 80 Years | Cogent Biosciences, Inc. | |
| Gene Therapy for Prostate Cancer That Returns After Radiation Therapy | NCT00110526 | Prostatic Neopl... Neoplasm Recurr... | Ad.hIL-12 | 40 Years - 75 Years | Icahn School of Medicine at Mount Sinai |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
